Clinical intervention trials evaluating the efficacy of antibody immunotherapy in type 1 diabetes are in progress. We tested effects on prediabetic islet antigen-specific autoreactive T cells of antithymocyte globulin (ATG) and humanized monoclonal antibodies against CD3 (ChAglyCD3) or CD25 (daclizumab) with regard to downmodulation of the target protein, proliferation, cytokine production, complement-dependent cytotoxicity (CDC), antibody-dependent cell cytotoxicity (ADCC), and survival. ATG...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Mechanisms of antibody immunotherapy on clonal islet reactive T cells.
If you are the owner of this record, you can report an update to it here: Report update to this record